Clinical trial
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated…
NCT00179699 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00179699 |
|---|---|
| Title | Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer |
| Official title | Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | CC-5013, pemetrexed |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Completion | Nov 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 7, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: